Home » Stocks » NVAX

Novavax, Inc. (NVAX)

Stock Price: $122.40 USD -2.65 (-2.12%)
Updated Jan 21, 2021 4:00 PM EST - Market closed
After-hours: $123.80 +1.40 (1.14%) Jan 21, 7:59 PM
Market Cap 8.01B
Revenue (ttm) 204.76M
Net Income (ttm) -272.53M
Shares Out 61.55M
EPS (ttm) -5.66
PE Ratio n/a
Forward PE 7.49
Dividend n/a
Dividend Yield n/a
Trading Day January 21
Last Price $122.40
Previous Close $125.05
Change ($) -2.65
Change (%) -2.12%
Day's Open 125.72
Day's Range 122.12 - 129.80
Day's Volume 2,466,113
52-Week Range 6.31 - 178.51

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Seeking Alpha - 16 hours ago

This article looks at the 17 companies listed on U.S. exchanges that had a higher total return than high-flying Tesla in 2020. The stocks tended to be microcap to small cap stocks in sectors t...

Other stocks mentioned: BEEM, BLNK, CELH, CODX, CRDF, GNPX, GRWG, KIRK, MARA, NLS, PLUG, RIOT, UAVS, VERI, VXRT, WTRH
The Dog of Wall Street - 17 hours ago

Take a look at a few trending biotech stocks and decide if this is something you want to invest in.

Other stocks mentioned: AXSM, JNJ
The Motley Fool - 21 hours ago

Last year's stock market star is getting ready for its big moment -- or, has it already happened?

The Motley Fool - 21 hours ago

These companies' vaccines could bring in billions of dollars in revenue.

Other stocks mentioned: VXRT
InvestorPlace - 1 day ago

After a monster 2020 rally, NVAX stock has been quiet so far in 2021. But with good news building, this year too should be a strong one.

Investopedia - 1 day ago

These are the small cap stocks with the best value, fastest growth, and most momentum for February 2021.

Other stocks mentioned: ATEN, EYE, SWBI, TROX, UIS, VERI, VHC, VXRT
InvestorPlace - 1 day ago

The NVAX stock battle now is heating up between the support below and the resistance above ... and the bulls have the momentum.

InvestorPlace - 1 day ago

Covid-19 pharma stocks like NVAX stock and BNTX stock are making headlines as Joe Biden promises to vaccinate 100 million Americans. The post Covid-19 Vaccine Roundup: 5 Pharma Stocks Making t...

Other stocks mentioned: AZN, BNTX, JNJ, MRNA, PFE
InvestorPlace - 1 day ago

Novavax has achieved considerable clinical success with its Covid-19 vaccine. However, NVAX stock is too expensive.

The Motley Fool - 1 day ago

Add these dirt cheap stocks to your portfolio while you still can.

Other stocks mentioned: CRTO, GME
The Motley Fool - 2 days ago

These stocks could be set for big gains in 2021 even after huge returns last year.

Other stocks mentioned: FVRR
Seeking Alpha - 3 days ago

Novavax: Parsing Through Insider Sales

The Motley Fool - 4 days ago

Experts give their opinion of a conservative pick and a riskier one.

Other stocks mentioned: JNJ
The Motley Fool - 5 days ago

This small biotech could be like the tortoise in Aesop's famous fable.

The Motley Fool - 5 days ago

Each has more to offer than just a COVID-19 vaccine.

Other stocks mentioned: JNJ, PFE
Zacks Investment Research - 6 days ago

In the latest trading session, Novavax (NVAX) closed at $127.43, marking a -1.96% move from the previous day.

Benzinga - 6 days ago

Novavax, Inc. (NASDAQ: NVAX) is beefing up its executive team as it prepares to release results of its late-stage coronavirus vaccine study and file for emergency use authorization. What Happe...

Investors Business Daily - 6 days ago

Novavax is making a play for a coronavirus vaccine, vs. giants like Pfizer, and other rivals like Moderna.

Zacks Investment Research - 6 days ago

While comparing stocks, if other factors are similar, investors can look out for the one with higher earnings yield. Stocks including GM, WGO, NVAX and MT score high in that parameter.

Other stocks mentioned: GM, MT, WGO
GlobeNewsWire - 6 days ago

GAITHERSBURG, Md., Jan. 15, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today...

The Motley Fool - 6 days ago

The next few weeks could be critical for the biotech's coronavirus vaccine prospects.

The Motley Fool - 6 days ago

Both of these biotechs could be big winners in the COVID-19 vaccine market.

Other stocks mentioned: MRNA
The Motley Fool - 1 week ago

Both of them already did it in 2020.

Other stocks mentioned: VXRT
InvestorPlace - 1 week ago

NVAX stock is poised for returns once its Phase 3 trial results come out, but potential investors should keep their eyes on the news. The post Novavax Will Likely Do Well Once Its Covid-19 Vac...

Zacks Investment Research - 1 week ago

3 Biotech Stocks Poised to Outperform Amid Coronavirus Pandemic

Other stocks mentioned: BPMC, HALO
Forbes - 1 week ago

Vaccine developer Novavax (NASDAQ: NVAX) is seen as a key player in the Coronavirus vaccine space. Here's a quick overview of what has been happening with the company over the last few weeks.

The Motley Fool - 1 week ago

Its risk-reward proposition is compelling.

Zacks Investment Research - 1 week ago

Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.

Zacks Investment Research - 1 week ago

Baxter's (BAX) BioPharma Solutions business inks deal to advance commercial-scale production and increase access for the COVID-19 vaccine in the U.K. and European markets.

The Motley Fool - 1 week ago

Investors seem perturbed by some reporting about top managers' recent financial moves.

InvestorPlace - 1 week ago

Novavax lost the race to be first with a Covid-19 vaccine, but NVX-CoV2373 is nearing approval. It will boost NVAX stock in 2021.

InvestorPlace - 1 week ago

Phase 3 trial delays are pushing NVAX stock down, but the biotech still has a reliable vaccine candidate expected to generate $3.9 billion. The post NVAX Stock Is Worth a Small Position but Va...

Business Wire - 1 week ago

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter BioPharma Solutions announced an agreement with Novavax to provide sterile manufacturing services for its COVID-19 vaccine candidate.

Other stocks mentioned: BAX
Reuters - 1 week ago

Top executives at U.S. pharmaceutical company Novavax Inc aren't waiting to see how well their COVID-19 vaccine works before they reap the financial rewards.

The Motley Fool - 1 week ago

Can this winner keep on succeeding?

The Motley Fool - 1 week ago

One big biotech and two small biotechs that share a common denominator: Great growth prospects.

Other stocks mentioned: EXEL, VRTX
Benzinga - 1 week ago

Novavax, Inc. (NASDAQ: NVAX) shares are higher Friday following a coronavirus vaccine supply deal the company announced with the Australian government. Deal Sealed: Novavax, based in Gaithersb...

GuruFocus - 1 week ago

The three securities listed below could be of interest to investors, as their forward price-earnings ratios are lower than the S&P 500's historical average of 15. The projections of future ear...

Other stocks mentioned: ABBV, MRK
InvestorPlace - 1 week ago

As Covid-19 vaccine leaders took the headlines, NVAX stock slipped into the shadows. However, the former group's setbacks could spell upside opportunity for the latter.

The Motley Fool - 1 week ago

Could they do it again in 2021?

Other stocks mentioned: VXRT
GlobeNewsWire - 2 weeks ago

GAITHERSBURG, Md., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today...

The Motley Fool - 2 weeks ago

Biotech, bitcoin, and renewable energy led the way.

Other stocks mentioned: BEEM, BLNK, BTBT, CRDF, MARA, NIO, RIOT, TRIL, VXRT
Seeking Alpha - 2 weeks ago

NVAX traded down in December, but there wasn't really any bad news from the company. NVAX did produce some good news with a US/Mexico trial of the company's COVID-19 vaccine getting underway.

The Motley Fool - 2 weeks ago

It trounced bitcoin in 2020 and has clear potential catalysts on the way.

The Motley Fool - 2 weeks ago

This may be the year of revenue.

Benzinga - 2 weeks ago

Novavax (NASDAQ: NVAX) saw its stock gain over 3,000% last year. But it could have even more room to run as the market will get only crazier for vaccines this year.

OTC PR Wire - 2 weeks ago

The re-opening narrative is dominating activity in the market and governs decisions being made in the business economy, and with good reason. Perhaps never before has so much value been tied t...

Other stocks mentioned: MRNA
GlobeNewsWire - 2 weeks ago

GAITHERSBURG, Md., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today...

Forbes - 2 weeks ago

Vaccine specialist Novavax - which is seen as a key player in the Covid-19 vaccine space - saw its stock price decline by about 20% over December. Here are a few possible reasons for the decline.

The Motley Fool - 2 weeks ago

Investors will soon have data to judge management's big projections.

About NVAX

Novavax, together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate that in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase III clinical trial for treating seasonal influenza in older adults. Its lead ad... [Read more...]

Industry
Biotechnology
IPO Date
Dec 5, 1995
CEO
Stanley Erck
Employees
522
Stock Exchange
NASDAQ
Ticker Symbol
NVAX
Full Company Profile

Financial Performance

In 2019, Novavax's revenue was $18.66 million, a decrease of -45.57% compared to the previous year's $34.29 million. Losses were -$132.69 million, -28.18% less than in 2018.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for Novavax stock is "Buy." The 12-month stock price forecast is 188.50, which is an increase of 54.00% from the latest price.

Price Target
$188.50
(54.00% upside)
Analyst Consensus: Buy